Novartis AG (NVS)

Market Cap	276.38B
Revenue (ttm)	56.37B
Net Income (ttm)	14.39B
Shares Out	1.92B
EPS (ttm)	7.30
PE Ratio	19.20
Forward PE	16.50
Dividend	$2.60 (1.80%)
Ex-Dividend Date	Mar 12, 2025

Volume	1,651,569
Open	143.78
Previous Close	143.15
Day's Range	142.89 - 144.76
52-Week Range	97.39 - 146.35
Beta	0.45
Analysts	Hold
Price Target	118.00 (-18.25%)
Earnings Date	Feb 4, 2026

About NVS

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Nov 18, 1991
• Employees: 75,883
• Stock Exchange: NYSE
• Ticker Symbol: NVS
• Website: https://www.novartis.com

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.

Analyst Summary

According to 5 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $118.0, which is a decrease of -18.25% from the latest price.

Price Target

$118.0

(-18.25% downside)

Analyst Consensus: Hold